Friday, 5 June 2020   Subscription to updates  RSS
11:00, 12 February 2018

Bench to Bedside: A Change of Heart, pt.1 – Embryonic Heart Development – Deepak Srivastava

Part 1: A Change of Heart: Embryonic Heart Development: Understanding the molecular pathways involved in normal heart development suggests treatments for both congenital and adult onset heart disease. Part 2: A Change of Heart: In vivo Cellular Reprograming: The introduction of specific genes into mammalian hearts caused fibroblasts to be reprogrammed to cardiac muscle cells. Talk Overview: During embryogenesis, the heart needs to form a specific three-dimensional shape or a child will be born with a defective heart. Srivastava and his colleagues hope that by better understanding the molecular pathways involved in normal heart development, it will possible to improve treatments for both congenital and adult onset heart disease. In his first talk, Srivastava describes studies from his lab and others which use animal models and induced pluripotent stem cells to elucidate many of the gene networks that determine cardiac cell fate. iPS cells have been particularly important for identifying a mutation in the human transcription factor GATA4.  By understanding the importance of GATA4 during heart development, it has been possible to develop a model that explains how cardiac specific genes can be activated while genes for other cell types are repressed. About half of the cells in an adult heart are cardiac myocytes, or muscle cells, and about half are cardiac fibroblasts or support cells.  Following a heart attack, muscle is lost and fibroblasts form scar tissue.  In his second talk, Srivastava asks whether our understanding of embryonic heart development can be used to reprogram fibroblasts to myocytes to repair damaged adult hearts. His lab showed that introducing the genes for 3 transcription factors important for embryonic cardiac development resulted in an increase in the number of myocytes in a mouse heart after an induced heart attack. Similar results were obtained in vivo in pigs and in vitro in human cells suggesting that in vivo cellular reprogramming by gene therapy has broad implications for organ regeneration. Speaker Biography: Deepak Srivastava is a Senior Investigator at the Gladstone Institute of Cardiovascular Disease and Director of the Roddenberry Center for Stem Cell Biology and Regenerative Medicine. He is also a Professor of Pediatrics and of Biochemistry and Biophysics at the University of California, San Francisco. Srivastava’s lab investigates the molecular events that instruct cardiac progenitor cells to differentiate into a functioning heart during embryogenesis.  Using their knowledge of cardiac development, Srivastava’s lab has reprogrammed non-muscle cells to function as heart muscle cells in the mouse allowing for repair of damaged heart tissue. This technique may allow for repair of human cardiac tissue following a heart attack. Learn more about Dr. Srivastava’s research here: iBiology


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2020 News: Today's News Headlines, Breaking News & Recent News from the World
Дизайн и поддержка: